Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar Carcinoma

Authors: Schalm, Stefanie S., O’Hearn, Erin, Wilson, Kevin, LaBranche, Timothy P., Silva, Grace, Zhang, Zhuo, DiPietro, Lucian, Bifulco, Neil, Woessner, Richard, Stransky, Nicolas, Sappal, Darshan, Campbell, Robert, Lobbardi, Riadh, Palmer, Michael, Kim, Joseph, Ye, Chaoyang, Dorsch, Marion, Lengauer, Christoph, Guzi, Timothy, Kadambi, Vivek, Garner, Andrew, Hoeflich, Klaus P.

Source: In Gastro Hep Advances 2023 2(3):307-321

Development of a quantification method for adenosine in tumors by LC-MS/MS with dansyl chloride derivatization

Authors: Goodwin, Kelly J., Gangl, Eric, Sarkar, Ujjal, Pop-Damkov, Petar, Jones, Natalie, Borodovsky, Alexandra, Woessner, Richard, Fretland, Adrian J.

Source: In Analytical Biochemistry 1 March 2019 568:78-88

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

Authors: Reilley, Matthew, McCoon, Patricia, Cook, Carl, Lyne, Paul, Kurzrock, Razelle, Kim, Youngsoo, Woessner, Richard, Younes, Anas, Nemunaitis, John, Fowler, Nathan, Curran, Michael, Liu, Qinying, Zhou, Tianyuan, Schmidt, Joanna, Jo, Minji, Lee, Samantha, Yamashita, Mason, Hughes, Steven, Fayad, Luis, Piha-Paul, Sarina, Nadella, Murali, Xiao, Xiaokun, Hsu, Jeff, Revenko, Alexey, Monia, Brett, MacLeod, A., Hong, David

Source: Journal for immunotherapy of cancer. 6(1):1-10

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185407302.0x000001&indx=1&recIds=ETOCvdc_100185407302.0x000001

Cytokine receptor signaling is required for the survival of ALK− anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations

Authors: Chen, Jing, Zhang, Yong, Petrus, Michael N., Xiao, Wenming, Nicolae, Alina, Raffeld, Mark, Pittaluga, Stefania, Bamford, Richard N., Nakagawa, Masao, Ouyang, Sunny Tianyi, Epstein, Alan L., Kadin, Marshall E., Del Mistro, Annarose, Woessner, Richard, Jaffe, Elaine S., Waldmann, Thomas A.

Source: Proceedings of the National Academy of Sciences of the United States of America, 2017 Apr 01. 114(15), 3975-3980.

Access URL: https://www.jstor.org/stable/26480848

Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2

Authors: Kettle, Jason G., Åstrand, Annika, Catley, Matthew, Grimster, Neil P., Nilsson, Magnus, Su, Qibin, Woessner, Richard

Source: Expert opinion on therapeutic patents. 27(2):145-161

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100106708640.0x000001&indx=1&recIds=ETOCvdc_100106708640.0x000001

Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1

Authors: Kettle, Jason G., Åstrand, Annika, Catley, Matthew, Grimster, Neil P., Nilsson, Magnus, Su, Qibin, Woessner, Richard

Source: Expert opinion on therapeutic patents. 27(2):127-143

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100106708634.0x000001&indx=1&recIds=ETOCvdc_100106708634.0x000001

Method of treatment using inhibitors of mitosis

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

Authors: Kuhn, Deborah J., Berkova, Zuzana, Jones, Richard J., Woessner, Richard, Bjorklund, Chad C., Ma, Wencai, Davis, R. Eric, Lin, Pei, Wang, Hua, Madden, Timothy L., Wei, Caimiao, Baladandayuthapani, Veerabhadran, Wang, Michael, Thomas, Sheeba K., Shah, Jatin J., Weber, Donna M., Orlowski, Robert Z.

Source: In Blood 18 October 2012 120(16):3260-3270

Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation

Authors: Davies, Kurtis D., Cable, P. LouAnn, Garrus, Jennifer E., Sullivan, Francis X., von Carlowitz, Ira, Huerou, Yvan Le, Wallace, Eli, Woessner, Richard D., Gross, Stefan

Source: Cancer biology & therapy. 12(9):788-796

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100053903860.0x000001&indx=1&recIds=ETOCvdc_100053903860.0x000001

BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer (NSCLC) driven by EGFR mutations

Authors: Tavera, Luz, Zhang, Zhuo, Wardwell, Scott, Job, Ebby, McGinn, Katie, Chen, Maxine, Iliou, Maria, Albayya, Faris, Campbell, John, Eno, Meredith, Fernando, Dilinie, Dineen, Tom, Ahmad, Omar, Wilson, Douglas, Barvian, Kevin, Hsieh, John, Medendorp, Clare, Timsit, Yoav, Guo, Jian, Perez, Nisha, Schalm, Stefanie, Woessner, Richard, Conti, Chiara

Source: Lung cancer. 165(S1):S37-S37

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100155623054.0x000001&indx=1&recIds=ETOCvdc_100155623054.0x000001

Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies

Authors: Ip, Carman K. M., Ng, Patrick K. S., Jeong, Kang Jin, Shao, S. H., Ju, Zhenlin, Leonard, P. G., Hua, Xu, Vellano, Christopher P., Woessner, Richard, Sahni, Nidhi, Scott, Kenneth L., Mills, Gordon B.

Source: Nature communications. 9(1)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100129874231.0x000001&indx=1&recIds=ETOCvdc_100129874231.0x000001

Method of Treatment Using Inhibitors of Mitosis

Prevention or Treatment of Cancer Using Integrin alphavbeta3 Antagonists in Combination with Other Agents

Immunosuppressive adenosine - a novel treatment target for multiple myeloma

Authors: Yang, Rui, Elsaadi, Samah, Misund, Kristine, Abdollahi, Pegah, Vandsemb, Esten, Moen, Siv H., Standal, Therese, Waage, Anders, Slørdahl, Tobias S., Rø, Torstein Baade, Rustad, Even Holth, Sundan, Anders, Hay, Carl, Cooper, Zachary A., Woessner, Richard, Borodovsky, Alexandra, Menu, Eline, Børset, Magne, Sponaas, Anne

Source: Clinical lymphoma, myeloma & leukemia. 19(S):e137-e138

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100091003268.0x000001&indx=1&recIds=ETOCvdc_100091003268.0x000001

78 - BLU-701 tumour suppression and intracranial activity as a single agent and in combination with BLU-945 in models of non-small cell lung cancer (NSCLC) driven by EGFR mutations

Authors: Tavera, Luz, Zhang, Zhuo, Wardwell, Scott, Job, Ebby, McGinn, Katie, Chen, Maxine, Iliou, Maria, Albayya, Faris, Campbell, John, Eno, Meredith, Fernando, Dilinie, Dineen, Tom, Ahmad, Omar, Wilson, Douglas, Barvian, Kevin, Hsieh, John, Medendorp, Clare, Timsit, Yoav, Guo, Jian, Perez, Nisha, Schalm, Stefanie, Woessner, Richard, Conti, Chiara

Source: In Lung Cancer March 2022 165 Supplement 1:S37-S37

KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells

Authors: Woessner Richard, Tytler Ewan M, Xie Yanhua, Kim Ki, Mor Gil, Alvero Ayesha B

Source: Journal of Translational Medicine, Vol 7, Iss 1, p 63 (2009)

Subject Terms: Medicine

File Description: electronic resource

Relation: http://www.translational-medicine.com/content/7/1/63; https://doaj.org/toc/1479-5876

Access URL: https://doaj.org/article/edfad35e31cd49838d642514b8067266

Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model.

Authors: Voronova, Veronika, Peskov, Kirill, Kosinsky, Yuri, Helmlinger, Gabriel, Chu, Lulu, Borodovsky, Alexandra, Woessner, Richard, Sachsenmeier, Kris, Shao, Wenlin, Kumar, Rakesh, Pouliot, Gayle, Merchant, Melinda, Kimko, Holly, Mugundu, Ganesh

Source: Frontiers in Immunology; 3/2/2021, pN.PAG-N.PAG, 12p

Subject Terms: ADENOSINES, TUMOR microenvironment, T cell differentiation, PHARMACOLOGY, ORDINARY differential equations, LYSIS

Identification of azabenzimidazoles as potent JAK1 selective inhibitors

Authors: Vasbinder, Melissa M., Alimzhanov, Marat, Augustin, Martin, Bebernitz, Geraldine, Bell, Kirsten, Chuaqui, Claudio, Deegan, Tracy, Ferguson, Andrew D., Goodwin, Kelly, Huszar, Dennis, Kawatkar, Aarti, Kawatkar, Sameer, Read, Jon, Shi, Jie, Steinbacher, Stefan, Steuber, Holger, Su, Qibin, Toader, Dorin, Wang, Haixia, Woessner, Richard, Wu, Allan, Ye, Minwei, Zinda, Michael

Source: In Bioorganic & Medicinal Chemistry Letters 1 January 2016 26(1):60-67

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.